Key facts
- This page summarizes Yinlin Jack Chen's Form 4 filing for Allogene Therapeutics, Inc. (ALLO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Aug 2023, 19:59.
Yinlin Jack Chen - 10 Aug 2023 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)
- Reporting relationship
- SVP, Finance
- Issuer ticker
- ALLO
- Reported as of
- 10 Aug 2023
- Net transaction value
- $0
- Reporting owner signature
- /s/Lillian Smith, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Yinlin Jack Chen filed Form 4 for Allogene Therapeutics, Inc. (ALLO) on 14 Aug 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALLO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +11,401
- Change %
- +15%
- Price
- $0.000000
- Shares after
- 88,881
- Date
- 10 Aug 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALLO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +39,160
- Change %
- Price
- $0.000000
- Shares after
- 39,160
- Date
- 10 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 39,160
- Exercise price
- $4.21
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
25% of the shares subject to the stock option shall vest on August 10, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.